Benefit of Digital Tools Used for Integrated Personalized Diabetes Management: Results From the PDM-ProValue Study Program.


Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
03 2020
Historique:
pubmed: 6 8 2019
medline: 3 8 2021
entrez: 6 8 2019
Statut: ppublish

Résumé

Integrated personalized diabetes management (iPDM) is a digitally supported therapeutic concept to improve patient-physician interaction to overcome the aspects of clinical inertia. Integrated personalized diabetes management can support decision making and improve therapeutic outcomes of suboptimally controlled persons with insulin-treated type 2 diabetes (T2D). In this paper, we report the results of an analysis of the PDM-ProValue study program on the effectiveness and perceived benefit of this approach, with a focus on how physicians used and assessed the digital tools provided for the iPDM process. The study program included two 12-month, prospective, controlled, cluster-randomized multicenter trials. A total of 101 practices participated with 907 patients. Practices were cluster-randomized to an intervention group and a control group. Digital tools for data visualization and analysis applied were used. HCP were asked to assess the use, relevance, and usefulness of the tools. A clear preference was stated for the visual overview over more statistically complex analyses. A total of 83% of the participants rated a high relevance of the "daily profile," 81% of the "total profile," and 68% the "risk illustrated by traffic light symbols" for the therapy decision. The overall iPDM process was very favorably rated with respect to structuredness and potential for personalized treatment and well accepted among health care professionals (HCP). Embedding digital tools in a structured process (iPDM) were proved to provide a benefit for insulin-treated T2D patients and their physicians. These results offer insight for further development and improvement of the tools and add information on how to overcome clinical inertia.

Sections du résumé

BACKGROUND
Integrated personalized diabetes management (iPDM) is a digitally supported therapeutic concept to improve patient-physician interaction to overcome the aspects of clinical inertia. Integrated personalized diabetes management can support decision making and improve therapeutic outcomes of suboptimally controlled persons with insulin-treated type 2 diabetes (T2D). In this paper, we report the results of an analysis of the PDM-ProValue study program on the effectiveness and perceived benefit of this approach, with a focus on how physicians used and assessed the digital tools provided for the iPDM process.
MATERIALS AND METHODS
The study program included two 12-month, prospective, controlled, cluster-randomized multicenter trials. A total of 101 practices participated with 907 patients. Practices were cluster-randomized to an intervention group and a control group. Digital tools for data visualization and analysis applied were used. HCP were asked to assess the use, relevance, and usefulness of the tools.
RESULTS
A clear preference was stated for the visual overview over more statistically complex analyses. A total of 83% of the participants rated a high relevance of the "daily profile," 81% of the "total profile," and 68% the "risk illustrated by traffic light symbols" for the therapy decision. The overall iPDM process was very favorably rated with respect to structuredness and potential for personalized treatment and well accepted among health care professionals (HCP).
CONCLUSIONS
Embedding digital tools in a structured process (iPDM) were proved to provide a benefit for insulin-treated T2D patients and their physicians. These results offer insight for further development and improvement of the tools and add information on how to overcome clinical inertia.

Identifiants

pubmed: 31378074
doi: 10.1177/1932296819867686
pmc: PMC7196877
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

240-249

Références

Diabetes Technol Ther. 2009 May;11(5):283-91
pubmed: 19425876
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
Am J Manag Care. 2012 Apr;18(3 Suppl):S43-8
pubmed: 22558941
Prim Care Diabetes. 2010 Dec;4(4):203-7
pubmed: 20719586
Diabetes Care. 2012 Jun;35(6):1279-84
pubmed: 22511257
Ann Pharmacother. 2014 May;48(5):562-70
pubmed: 24586059
J Diabetes Sci Technol. 2016 May 03;10(3):772-81
pubmed: 26645793
Diabetes Res Clin Pract. 2018 Oct;144:200-212
pubmed: 30205184
Diabetol Metab Syndr. 2015 Jan 15;7:2
pubmed: 25904987
Diabetes Technol Ther. 2012 Jan;14(1):59-64
pubmed: 21988274
Diabetes Technol Ther. 2011 Aug;13(8):797-802
pubmed: 21568751
J Diabetes Sci Technol. 2016 Feb 10;10(2):414-20
pubmed: 26864513
Diabetes Res Clin Pract. 2012 Oct;98(1):5-10
pubmed: 22917639
J Behav Med. 2002 Feb;25(1):17-31
pubmed: 11845556
N Engl J Med. 2013 Apr 25;368(17):1613-24
pubmed: 23614587
J Diabetes Sci Technol. 2011 Nov 01;5(6):1529-48
pubmed: 22226276
Diabetologia. 2015 Mar;58(3):429-42
pubmed: 25583541
Cochrane Database Syst Rev. 2015 Mar 03;(3):CD010523
pubmed: 25733495

Auteurs

Lutz Heinemann (L)

Science Consulting in Diabetes GmbH, Neuss, Germany.

Wendelin Schramm (W)

GECKO Institut, Hochschule Heilbronn, Germany.

Helena Koenig (H)

Roche Diabetes Care GmbH, Mannheim, Germany.

Annette Moritz (A)

Roche Diabetes Care Deutschland GmbH, Mannheim, Germany.

Iris Vesper (I)

Roche Diabetes Care GmbH, Mannheim, Germany.

Joerg Weissmann (J)

Roche Diabetes Care Deutschland GmbH, Mannheim, Germany.

Bernhard Kulzer (B)

FIDAM (Forschungsinstitut Diabetes Akademie Bad Mergentheim), Bad Mergentheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH